2. Search Result
Search Result
Results for "

fatty acid synthase,FASN

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12364A
    trans-C75

    (±)-C75

    		 Fatty Acid Synthase (FASN) Cancer
    trans-C75 ((±)-C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.
    trans-C75
  • HY-111777
    FASN-IN-1
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) Cancer
    FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56 .
    FASN-IN-1
  • HY-U00436
    FASN-IN-3

    		Fatty Acid Synthase (FASN) Cancer
    FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A .
    FASN-IN-3
  • HY-112522
    HS79

    		Fatty Acid Synthase (FASN) Cancer
    HS-79 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-79 is able to inhibit the incorporation of tritiated acetate into lipids with an IC50 of 1.57 μM.
    HS79
  • HY-112522A
    HS80

    		Fatty Acid Synthase (FASN) Cancer
    HS-80 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-80 is able to inhibit the incorporation of tritiated acetate into lipids with an IC50 of 7.13 μM.
    HS80
  • HY-112829
    Denifanstat
    1 Publications Verification

    TVB-2640; FASN-IN-2; ASC-40

    		 Fatty Acid Synthase (FASN) Metabolic Disease Cancer
    Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research .
    Denifanstat
  • HY-12364
    C75
    Maximum Cited Publications
    21 Publications Verification

    		 Fatty Acid Synthase (FASN) Cancer
    C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
    C75
  • HY-121250
    Fasnall

    		Fatty Acid Synthase (FASN) Apoptosis Cancer
    Fasnall is a selective fatty acid synthase (FASN) inhibitor with an IC50 of 3.71 μM. Fasnall induces apoptosis in HER2 + breast cancer cell lines. Fasnall shows potent anti-tumor activities .
    Fasnall
  • HY-B0218
    Orlistat
    5+ Cited Publications

    Tetrahydrolipstatin; Ro-18-0647

    		 Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease Cancer
    Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .
    Orlistat
  • HY-12648
    FASN-IN-4

    		Fatty Acid Synthase (FASN) SARS-CoV Infection Metabolic Disease
    FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29) . FASN-IN-4 also inhibits SARS-CoV-2 with an EC50 of 18.6 nM .
    FASN-IN-4
  • HY-12648A
    FASN-IN-4 tosylate
    3 Publications Verification

    		 Fatty Acid Synthase (FASN) SARS-CoV Infection Metabolic Disease
    FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29) . FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC50 of 18.6 nM .
    FASN-IN-4 tosylate
  • HY-12364B
    (−)-C75

    		Fatty Acid Synthase (FASN) Cancer
    (−)-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
    (−)-C75
  • HY-A0210
    Cerulenin
    5 Publications Verification

    		 Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic Infection Metabolic Disease
    Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .
    Cerulenin
  • HY-120394
    TVB-3166
    5+ Cited Publications

    		 Fatty Acid Synthase (FASN) Apoptosis Cancer
    TVB-3166 is an orally-available, reversible, and selective fatty acid synthase (FASN) inhibitor with IC50s of 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively. TVB-3166 induces apoptosis, and inhibits in-vivo xenograft tumor growth .
    TVB-3166
  • HY-120062
    TVB-3664
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) Cancer
    TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC50 values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression .
    TVB-3664
  • HY-B0218R
    Orlistat (Standard)
    5+ Cited Publications

    Tetrahydrolipstatin (Standard); Ro-18-0647 (Standard)

    		 Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease Cancer
    Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity .?Anti-atherosclerotic?effect .
    Orlistat (Standard)
  • HY-12325
    GSK2194069
    2 Publications Verification

    		 Fatty Acid Synthase (FASN) Cancer
    GSK2194069 is a potent inhibitor of β-ketoyl reductase (KR) of fatty acid synthase (FASN), with an IC50 value of 7.7 nM. GSK2194069 shows specifically inhibitory effect on FAS expressing cancer cells, by acting potent efficacy on acetoacetyl-CoA, NADPH with IC50 or Ki values of 4.8 nM and 5.6 nM, respectively .
    GSK2194069
  • HY-111551
    FT113
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) Cancer
    FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC50 of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC50, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo .
    FT113
  • HY-117769
    GSK837149A

    		Fatty Acid Synthase (FASN) Metabolic Disease
    GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer .
    GSK837149A
  • HY-110354
    UCM05

    G28UCM

    		 Fatty Acid Synthase (FASN) Bacterial Antibiotic Infection Cancer
    UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. UCM05 is a Filamentous temperature-sensitive protein Z (FtsZ) inhibitor and inhibits the growth of the Gram-positive bacterium B. subtilis with MIC values of 100 μM but lack activity on the Gram-negative bacterium E. coli.
    UCM05
  • HY-149540
    CTL-06

    		Fatty Acid Synthase (FASN) Cancer
    CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC50: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .
    CTL-06
  • HY-149541
    CTL-12

    		Fatty Acid Synthase (FASN) Cancer
    CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC50: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .
    CTL-12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: